233 related articles for article (PubMed ID: 36951152)
21. A Case of Cutaneous Blastic Plasmacytoid Dendritic Cell Neoplasm Treated With a Bcl-2 Inhibitor.
Egger A; Coello D; Kirsner RS; Brehm JE
J Drugs Dermatol; 2021 May; 20(5):550-551. PubMed ID: 33938687
[TBL] [Abstract][Full Text] [Related]
22. Tagraxofusp: First Global Approval.
Syed YY
Drugs; 2019 Apr; 79(5):579-583. PubMed ID: 30859413
[TBL] [Abstract][Full Text] [Related]
23. Long-Term Benefits of Tagraxofusp for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm.
Pemmaraju N; Sweet KL; Stein AS; Wang ES; Rizzieri DA; Vasu S; Rosenblat TL; Brooks CL; Habboubi N; Mughal TI; Kantarjian H; Konopleva M; Lane AA
J Clin Oncol; 2022 Sep; 40(26):3032-3036. PubMed ID: 35820082
[No Abstract] [Full Text] [Related]
24. Relapse of tagraxofusp treated blastic plasmacytoid dendritic cell neoplasm with loss of CD123 expression.
Gulati R; Abu-Salah A; Salous T; Nassiri M
J Hematop; 2022 Mar; 15(1):35-39. PubMed ID: 38358597
[TBL] [Abstract][Full Text] [Related]
25. Updates in Novel Therapies for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN).
Economides MP; Rizzieri D; Pemmaraju N
Curr Hematol Malig Rep; 2019 Dec; 14(6):515-522. PubMed ID: 31853773
[TBL] [Abstract][Full Text] [Related]
26. Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm.
Pemmaraju N; Lane AA; Sweet KL; Stein AS; Vasu S; Blum W; Rizzieri DA; Wang ES; Duvic M; Sloan JM; Spence S; Shemesh S; Brooks CL; Balser J; Bergstein I; Lancet JE; Kantarjian HM; Konopleva M
N Engl J Med; 2019 Apr; 380(17):1628-1637. PubMed ID: 31018069
[TBL] [Abstract][Full Text] [Related]
27. Tagraxofusp for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): A Brief Report on Emerging Data.
Beziat G; Ysebaert L
Onco Targets Ther; 2020; 13():5199-5205. PubMed ID: 32606740
[TBL] [Abstract][Full Text] [Related]
28. CD38 and BCL2 expression guides treatment with daratumumab and venetoclax in tagraxofusp-refractory blastic plasmacytoid dendritic cell neoplasm (BPDCN) featuring dynamic loss of CD123.
Hu X; Ediriwickrema A; Saleem A; Tan B; Pemmaraju N; Mannis GN
Leuk Res; 2024 Apr; 139():107479. PubMed ID: 38492495
[No Abstract] [Full Text] [Related]
29. Targeting CD123 in blastic plasmacytoid dendritic cell neoplasm using allogeneic anti-CD123 CAR T cells.
Cai T; Gouble A; Black KL; Skwarska A; Naqvi AS; Taylor D; Zhao M; Yuan Q; Sugita M; Zhang Q; Galetto R; Filipe S; Cavazos A; Han L; Kuruvilla V; Ma H; Weng C; Liu CG; Liu X; Konoplev S; Gu J; Tang G; Su X; Al-Atrash G; Ciurea S; Neelapu SS; Lane AA; Kantarjian H; Guzman ML; Pemmaraju N; Smith J; Thomas-Tikhonenko A; Konopleva M
Nat Commun; 2022 Apr; 13(1):2228. PubMed ID: 35484100
[TBL] [Abstract][Full Text] [Related]
30. Novel Therapeutic Approaches in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Era of Targeted Therapy.
Wilson NR; Konopleva M; Khoury JD; Pemmaraju N
Clin Lymphoma Myeloma Leuk; 2021 Nov; 21(11):734-740. PubMed ID: 34226167
[TBL] [Abstract][Full Text] [Related]
31. North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need.
Pemmaraju N; Kantarjian H; Sweet K; Wang E; Senapati J; Wilson NR; Konopleva M; Frankel AE; Gupta V; Mesa R; Ulrickson M; Gorak E; Bhatia S; Budak-Alpdogan T; Mason J; Garcia-Romero MT; Lopez-Santiago N; Cesarman-Maus G; Vachhani P; Lee S; Bhatt VR; Blum W; Walter RB; Bixby D; Gojo I; Duvic M; Rampal RK; de Lima M; Foran J; Fathi AT; Hall AC; Jacoby MA; Lancet J; Mannis G; Stein AS; Mims A; Rizzieri D; Olin R; Perl A; Schiller G; Shami P; Stone RM; Strickland S; Wieduwilt MJ; Daver N; Ravandi F; Vasu S; Guzman M; Roboz GJ; Khoury J; Qazilbash M; Aung PP; Cuglievan B; Madanat Y; Kharfan-Dabaja MA; Pawlowska A; Taylor J; Tallman M; Dhakal P; Lane AA
Blood; 2023 Feb; 141(6):567-578. PubMed ID: 36399715
[TBL] [Abstract][Full Text] [Related]
32. Recent developments in the treatment of blastic plasmacytoid dendritic cell neoplasm.
Economides MP; Konopleva M; Pemmaraju N
Ther Adv Hematol; 2019; 10():2040620719874733. PubMed ID: 31579499
[TBL] [Abstract][Full Text] [Related]
33. In vivo and in vitro sensitivity of blastic plasmacytoid dendritic cell neoplasm to SL-401, an interleukin-3 receptor targeted biologic agent.
Angelot-Delettre F; Roggy A; Frankel AE; Lamarthee B; Seilles E; Biichle S; Royer B; Deconinck E; Rowinsky EK; Brooks C; Bardet V; Benet B; Bennani H; Benseddik Z; Debliquis A; Lusina D; Roussel M; Solly F; Ticchioni M; Saas P; Garnache-Ottou F
Haematologica; 2015 Feb; 100(2):223-30. PubMed ID: 25381130
[TBL] [Abstract][Full Text] [Related]
34. New perspectives in genetics and targeted therapy for blastic plasmacytoid dendritic cell neoplasm.
Zhang X; Sun J; Yang M; Wang L; Jin J
Crit Rev Oncol Hematol; 2020 May; 149():102928. PubMed ID: 32234682
[TBL] [Abstract][Full Text] [Related]
35. Blastic Plasmacytoid Dendritic Cell Neoplasm: Progress in Cell Origin, Molecular Biology, Diagnostic Criteria and Therapeutic Approaches.
Cheng W; Yu TT; Tang AP; He Young K; Yu L
Curr Med Sci; 2021 Jun; 41(3):405-419. PubMed ID: 34218354
[TBL] [Abstract][Full Text] [Related]
36. Liposomal Daunorubicin and Cytarabine, a Potential Therapy for Blastic Plasmacytoid Dendritic Cell Neoplasm.
Ashok Kumar P; Ombada M; Pemmasani G; Tambe A; Banki K; Gentile T
J Investig Med High Impact Case Rep; 2022; 10():23247096221127114. PubMed ID: 36341907
[TBL] [Abstract][Full Text] [Related]
37. Blastic Plasmacytoid Dendritic Cell Neoplasm-Current Insights.
Venugopal S; Zhou S; El Jamal SM; Lane AA; Mascarenhas J
Clin Lymphoma Myeloma Leuk; 2019 Sep; 19(9):545-554. PubMed ID: 31281107
[TBL] [Abstract][Full Text] [Related]
38. [Blastic plasmacytoid dendritic cell neoplasm (BPDCN) : A rare hematologic neoplasm with frequent cutaneous involvement].
Nguyen K; Korsing S; Mansour Y; Meier K
Dermatologie (Heidelb); 2023 Oct; 74(10):787-792. PubMed ID: 37407876
[TBL] [Abstract][Full Text] [Related]
39. Targeting CD123 in AML.
Lane AA
Clin Lymphoma Myeloma Leuk; 2020 Sep; 20 Suppl 1():S67-S68. PubMed ID: 32862874
[TBL] [Abstract][Full Text] [Related]
40. Blastic plasmacytoid dendritic cell neoplasm: emerging developments and special considerations for 2023.
Pemmaraju N; Kantarjian H
Clin Adv Hematol Oncol; 2023 May; 21(5):257-264. PubMed ID: 37145496
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]